ライフサイエンスコーパス: allotransplantation

1 te allografts (VCAs; a.k.a. composite tissue allotransplantation).

2 d for the generation of memory T cells after allotransplantation.

3 lymphoid tissues as early as 3 h post-islet allotransplantation.

4 ly being investigated in a clinical trial of allotransplantation.

5 in vivo, in models of alloimmune priming and allotransplantation.

6 body formation during the early period after allotransplantation.

7 framework for approaching the endothelium in allotransplantation.

8 on the restoration of facial deformities by allotransplantation.

9 timulatory pathway to a murine model of limb allotransplantation.

10 aft-versus-host disease and recurrence after allotransplantation.

11 s on the inflammatory processes triggered by allotransplantation.

12 ising combination for clinical evaluation in allotransplantation.

13 ns for the immunotherapy of autoimmunity and allotransplantation.

14 ay be equally applicable to composite-tissue allotransplantation.

15 d to the development of OAD following airway allotransplantation.

16 on plays a role in the poor success of islet allotransplantation.

17 erivative (RAD), in cynomolgus monkey kidney allotransplantation.

18 solution to the shortage of donor organs for allotransplantation.

19 in a rat hindlimb model of composite tissue allotransplantation.

20 mune-mediated diseases and for outcome after allotransplantation.

21 zation, prior LVAD support, or prior cardiac allotransplantation.

22 in patients (n = 29) who had undergone lung allotransplantation.

23 ne reactivity, when placed in the context of allotransplantation.

24 a promising agent for clinical use in human allotransplantation.

25 dness and is a major complication of corneal allotransplantation.

26 most common donor-associated infection after allotransplantation.

27 t survival in the murine model of orthotopic allotransplantation.

28 ic those arising during MHC mismatched human allotransplantation.

29 ransplantation as a practical alternative to allotransplantation.

30 ntation and a rhesus macaque model of kidney allotransplantation.

31 ents were selected for transition to cardiac allotransplantation.

32 kidney quality and function in human kidney allotransplantation.

33 proteinuria, a phenotype that is not seen in allotransplantation.

34 pecialized center for vascularized composite allotransplantation.

35 ver, outcomes are considered inferior to NHP-allotransplantation.

36 pig liver transplant as a clinical bridge to allotransplantation.

37 uality data on secondary corneal endothelial allotransplantation.

38 a mouse OB model after heterotopic tracheal allotransplantation.

39 into antibody-secreting cells in response to allotransplantation.

40 tion or nonhuman primate-to-nonhuman primate allotransplantation.

41 imism for its potential as an alternative to allotransplantation.

42 ulating the development of new antibodies in allotransplantation.

43 ograft exposure does not preclude subsequent allotransplantation.

44 ponses using mouse models of heart and renal allotransplantation.

45 ring strategies following pancreas and islet allotransplantation.

46 on outcomes in facial vascularized composite allotransplantation.

47 vel aspect of the role of innate immunity in allotransplantation.

48 boons to assess its potential as a bridge to allotransplantation.

49 eered pig liver xenotransplantation to liver allotransplantation.

50 the potential of the BM as a site for islet allotransplantation.

51 lementation of paediatric vascular composite allotransplantation.

52 pproximate the antibody binding occurring in allotransplantation.

53 ffering new perspectives in composite tissue allotransplantation.

54 an primate models of autoimmune diseases and allotransplantation.

55 l after anti-CD25 induction therapy in islet allotransplantation.

56 le additional risk involved with parathyroid allotransplantation.

57 d the risk/benefit balance in bilateral hand allotransplantation.

58 rapy might improve graft survival in cardiac allotransplantation.

59 etic with streptozotocin and underwent islet allotransplantation.

60 to play a significantly greater role than in allotransplantation.

61 confirmed acceptance of PSCs in MHC-matched allotransplantation.

62 tment of rejection in vascularized composite allotransplantation.

63 kidney quality and function in human kidney allotransplantation.

64 duction, immunosuppressive therapy, or islet allotransplantation.

65 play a significant role in composite tissue allotransplantation.

66 prevention of antibody-mediated rejection in allotransplantation.

67 to address the shortage of human organs for allotransplantation.

68 m deceased individuals continues to restrict allotransplantation.

69 ection after ABO-compatible HLA-incompatible allotransplantation.

70 an outbred non-human primate model of renal allotransplantation.

71 ascular arterial thrombosis in murine aortic allotransplantation.

72 ngle surgical procedure using composite face allotransplantation.

73 tion under stress conditions such as cardiac allotransplantation.

74 de as well as for the graft to survive after allotransplantation.

75 nimum theoretical standard to work toward in allotransplantation.

76 nsplanted along with islets during auto- and allotransplantations.

77 vival was significantly inferior to clinical allotransplantation (6 months, 36.1% vs. 94.0%; p < .001

78 ysis demonstrated more cellular rejection in allotransplantation (62.8% vs. 3.1%, p < .001) and more

79 The first human facial allotransplantation, a 38-year-old woman, was performed

80 ational Society on Hand and Composite Tissue Allotransplantation, a section of The Transplantation So

81 unosuppression in mice 30 days before aortic allotransplantation across C57Bl/ 10J (H2b)-->C3H (H2k)

82 The authors performed 30 hind-limb allotransplantations across the MHC barrier between Brow

83 010 over both CyA and SAHA, in the models of allotransplantation adopted.

84 the first report suggestive of CR in a face allotransplantation after immunosuppression minimization

85 regulated as a drug, which has led to islet allotransplantation (allo-ITx) becoming a standard-of-ca

86 tory functions, which could be beneficial in allotransplantation (allo-Tx).

87 PTN) began overseeing vascularized composite allotransplantation/allografts (VCA) in the United State

88 er a pig xenograft would preclude subsequent allotransplantation, although the data available suggest

89 nomolgus macaque model of intrahepatic islet allotransplantation and a rhesus macaque model of kidney

90 essed the feasibility of rat brachial plexus allotransplantation and analyzed its functional outcomes

91 at reducing inappropriate immune reaction in allotransplantation and autoimmune diseases.

92 d CD86 can elicit host immune suppression in allotransplantation and autoimmunity.

93 is study, we extended our regimen to cardiac allotransplantation and compared the immunological respo

94 strategies for integrating sex and gender in allotransplantation and donation research during study d

95 and IL-6 is markedly upregulated after heart allotransplantation and lymphoablation.

96 ejection and could potentially be applied to allotransplantation and prevention of the autoimmune rec

97 opportunities to replicate aspects of human allotransplantation and to assist in the development of

98 toxic, highly-targeted conditioning agent in allotransplantation and tolerance protocols.

99 Based on experience in allotransplantation and with preclinical models, viral i

100 ndent cellular cytotoxicity, to human AMR in allotransplantation and xenotransplantation and illustra

101 ory response influences the outcome of organ allotransplantation and xenotransplantation.

102 ions of the T-bet + B-cell subset outside of allotransplantation, and consider the relevance of this

103 ght reduce subsequent acute rejection, after allotransplantation, and coronary allograft vasculopathy

104 (MHC) are the primary barrier to successful allotransplantation, and here we describe class I MHC mo

105 recipients of successful intrahepatic islet allotransplantation, and in matched control subjects.

106 assist device (LVAD) support, prior cardiac allotransplantation, and pulmonary hypertension, are und

107 njury as manifested in ischemia-reperfusion, allotransplantation, and various vascular diseases.

108 We tested PG27 in rat cardiac and renal allotransplantation, and we examined the immunosuppressi

109 evidence that autoimmune responses following allotransplantation are damaging and cause accelerated g

110 Short-term outcomes in allotransplantation are excellent due to technical and p

111 The complications in composite tissue allotransplantation are similar to those usually reporte

112 Vascularized composite allotransplantations are complex procedures with substan

113 , support the continued application of islet allotransplantation as a treatment modality for type 1 d

114 The extent to which renal allotransplantation - as compared with long-term dialysi

115 (1) OAD occurs not only after tracheal allotransplantation but also after xenotransplantation.

116 hould be fully acceptable as a candidate for allotransplantation but should be unlikely ever to recei

117 have use as an adjunctive agent for clinical allotransplantation, but using the dosing regimens we us

118 Before a human clinical trial of hepatocyte allotransplantation can be attempted, preliminary experi

119 al skin irritation in vascularized composite allotransplantation can trigger localized skin inflammat

120 for investigators performing total human eye allotransplantation clinical trials, as well as for opht

121 ), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P

122 Vascularized brachial plexus allotransplantation could offer the best nerve graft ful

123 Composite tissue allotransplantation (CTA) has been recently introduced a

124 Numerous experiments in composite tissue allotransplantation (CTA) have identified skin as the mo

125 Composite tissue allotransplantation (CTA) is a recently introduced optio

126 The science of composite tissue allotransplantation (CTA) is rooted in progressive think

127 Composite tissue allotransplantation (CTA) represents a surgical technolo

128 deal model to study various composite tissue allotransplantation (CTA)-related problems, we designed

129 After allotransplantation, cytomegalovirus (CMV) may be transm

130 Allotransplantations (DA-->BN) were performed (n=8), wit

131 ALB/c and NOD mice and that successful islet allotransplantation depends on the degree of hyperglycem

132 After single lung allotransplantation, dogs were maintained on standard tr

133 ic stimulation that occurs, among others, in allotransplantation due to constant exposure to donor al

134 n = 4) who underwent facial composite tissue allotransplantation (FCTA) at our center between April 2

135 se data highlight the potential for clinical allotransplantation for globe loss.

136 sion is being developed as a bridge to liver allotransplantation for patients with fulminant hepatic

137 mples from patients awaiting cadaveric renal allotransplantation for reactivity against: 1) human; 2)

138 Until recently, islet allotransplantation for type 1 diabetic patients has bee

139 The hindlimb allotransplantation from Brown-Norway to Lewis rats was

140 Seven outbred baboons underwent renal allotransplantation from major histocompatibility comple

141 tes after heterotopic partial facial segment allotransplantation from major histocompatibility comple

142 bred juvenile rhesus monkeys underwent renal allotransplantation from MHC-disparate donors.

143 Facial vascularized composite allotransplantation (fVCA) presents an established appro

144 Facial vascularized composite allotransplantation (fVCA) represents a reconstructive a

145 sis on their potential for use as models for allotransplantation, graft versus host disease, and rege

146 In multivariate analyses, allotransplantation had higher TRM and lower disease rec

147 Although heterologous vascular composite allotransplantation has become a burgeoning treatment op

148 Vascularized composite allotransplantation has become established as a clinical

149 Hepatocyte allotransplantation has been performed successfully in s

150 During the last decade, face allotransplantation has been shown to be a revolutionary

151 pite technical feasibility, composite tissue allotransplantation has not been applied clinically beca

152 nic rejection (CR) in vascularized composite allotransplantation has not been included in the Banff c

153 The success of allotransplantation has paradoxically led to a shortage

154 in the supply of human organs available for allotransplantation has turned attention toward the use

155 ong-term outcomes of both pancreas and islet allotransplantation have been compromised by difficultie

156 menon repeats itself after second same donor allotransplantation, hoping to determine whether accepta

157 he widespread clinical use of reconstructive allotransplantation if protocols to achieve this could b

158 allotransplantation was inaugurated by hand allotransplantation in 1998, giving rise to many controv

159 Composite tissue allotransplantation in a 30-year-old male was used as a

160 lts in clinical trials, in contrast to islet allotransplantation in animal models, which have demonst

161 LA-4 pathway, and belatacept (n=5) in kidney allotransplantation in baboons.

162 mediated barriers that continue to challenge allotransplantation in humans.

163 cted adult patients and as a bridge to heart allotransplantation in infant patients with complex cong

164 in contrast to clinical experience with AB-I allotransplantation in infants, who cease producing only

165 Aortic allotransplantation in mice has been well established as

166 rotocol for fully MHC-mismatched bone marrow allotransplantation in mice involving transient immunosu

167 TG) for effects on anti-mATG Abs and cardiac allotransplantation in mice.

168 and LFA-1 in the challenging model of islet allotransplantation in NOD mice.

169 good tolerability in a preclinical model of allotransplantation in nonhuman primates and thus has in

170 monoclonal antibody (hu5C8) allows for renal allotransplantation in outbred, MHC-mismatched rhesus mo

171 itable alternative site for pancreatic islet allotransplantation in patients with type 1 diabetes.

172 doses of corticosteroid hormones after renal allotransplantation in the era of cyclosporine and tacro

173 emonstrate that immune tolerance after organ allotransplantation in the rat is associated with a repr

174 Islet allotransplantation in the United States (US) is facing

175 poglycemia and 2) whether intrahepatic islet allotransplantation in type I diabetic patients and cons

176 Unlike human allotransplantation, in which the important antigenic di

177 Only the allotransplantation including all 5 roots as donor nerve

178 st that activation of donor T cells after SB allotransplantation induces production of a Th1-like pro

179 After skin allotransplantation, intercellular transfer of donor maj

180 ce of kidney allograft tolerance since renal allotransplantation into CD8-KO recipients resulted in a

181 Allotransplantation into immunosuppressed individuals re

182 common cause of late graft failure in renal allotransplantation is chronic antibody-mediated rejecti

183 The need for a clinical "bridge" to allotransplantation is clear.

184 Whole liver allotransplantation is limited by a shortage of human do

185 The decreased recurrence after allotransplantation is offset by increased TRM.

186 between bone marrow transplantation and limb allotransplantation is required, making such protocols i

187 h complex congenital heart problems, cardiac allotransplantation is sometimes the best therapeutic op

188 ined HLA-matched donor bone marrow and renal allotransplantation is the first example of an intention

189 A major limitation of organ allotransplantation is the insufficient supply of donor

190 een this suggested regimen and those used in allotransplantation is the replacement of a calcineurin

191 cold ischemia (CI) in vascularized composite allotransplantation is unknown.

192 Cardiac allotransplantation is warranted in children with end-st

193 Pregnancy after allotransplantations is becoming a more common occurrenc

194 on of graft survival after intraportal islet allotransplantation (ITx) in rats: 7.2 days in the contr

195 present in their serum suggesting that, like allotransplantation, late xenograft failure may be drive

196 human cytomegalovirus (HCMV) infection after allotransplantation led us to evaluate whether baboon cy

197 yeloablative preconditioning and barriers to allotransplantation limit this therapy to children with

198 Composite tissue allotransplantation may have different immunosuppressive

199 natives to the current technology of cardiac allotransplantation may include xenotransplantation and/

200 plants using nonmyeloablative regimens (mini-allotransplantations) may hold promise for more widely e

201 mobilized and collected T cells, which after allotransplantation, might positively affect the inciden

202 t arteriosclerosis in a rat orthotopic aorta allotransplantation model (Brown Norway to Lewis).

203 minates this delay period in a rat hind limb allotransplantation model by performing mixed allogeneic

204 a non-human primate facial composite tissue allotransplantation model to investigate strategies to a

205 "Third-party" controls and a skin allotransplantation model were used to confirm DSAs' spe

206 on with cyclosporine (CsA) in a rat hindlimb allotransplantation model with a major antigenic mismatc

207 In a heterotopic cardiac allotransplantation model, CD73 deficiency in either don

208 leflunomide (5, 15, and 35 mg/kg/day) in the allotransplantation model.

209 to prevent graft rejection in a mouse heart allotransplantation model; the highest dose tested (1.5

210 y function after single-donor clinical islet allotransplantation (n = 7).

211 This technology will allow successful allotransplantation of cells/organs even between Major H

212 p 1 Cynomolgus monkeys (n=6) underwent TIR + allotransplantation of hematopoietic cells and a kidney

213 Numerous studies have reported successful allotransplantation of hepatocytes.

214 Furthermore, allotransplantation of HPCs from APAP+ISO-treated mice t

215 Allotransplantation of MSCs may alleviate some of these

216 nce that reducing oxidative stress following allotransplantation of PVPON/TA-encapsulated islets can

217 ble immune tolerance supporting vascularized allotransplantation offers the possibility of extending

218 for neonates and infants, either in lieu of allotransplantation or as a bridge until an allograft be

219 As a theoretical alternative to allotransplantation, patient-derived bioartificial myoca

220 d in 64 liver transplant patients, 59 kidney allotransplantation patients and six lung transplant pat

221 The study included 5 cases of bilateral hand allotransplantation performed in a single center, with a

222 surgical free tissue transfer or solid organ allotransplantation procedures can facilitate early diag

223 However, current allotransplantation protocols involve genotoxic conditio

224 ecurrence rates were 21%, 43%, and 58% after allotransplantation, purged autotransplantation, and unp

225 th hepatic contraindications for liver islet allotransplantation receiving a single intra-BM islet in

226 al mucosa of 9 facial vascularized composite allotransplantation recipients were retrospectively anal

227 ory receptors on T cells and modification of allotransplantation regimens have all produced new tumor

228 he role of CD4+ and CD8+ cells in initiating allotransplantation rejection.

229 Kidney allotransplantation remains the preferred treatment for

230 BACKGROUND Following allotransplantation, renal ischemia-reperfusion (I/R) in

231 useful vascularized complete brachial plexus allotransplantation rodent model with successful forelim

232 In allotransplantation, several unique factors influence th

233 Ischemia times in vascularized composite allotransplantation should be kept as short as possible

234 In rodents, spleen allotransplantation (SpTx) induces tolerance.

235 Although protocols varied, NHP-allotransplantation survival (1, 3, 12months, 67.5%, 37.

236 strategy to increase vascularized composite allotransplantation survival.

237 together, our results suggest that following allotransplantation, T cell responses to donor antigens

238 In July, 2015, our vascularised composite allotransplantation team did the first bilateral hand an

239 trategy for tolerance induction in laryngeal allotransplantation that permits escape from chronic imm

240 n this study, using a murine model of aortic allotransplantation, the role of blockade of signaling t

241 In allotransplantation, the source of the allograft, for ex

242 In allotransplantation, the successful transplantation of h

243 After allotransplantation, there was up-regulation of all 11 c

244 e our initial experience with abdominal wall allotransplantation to facilitate abdominal closure.

245 y of conventional BMT and expands the use of allotransplantation to non-HLA-matched donors.

246 monitoring in facial vascularized composite allotransplantation traditionally focuses on skin biopsi

247 38 months and 47 +/- 40 months after cardiac allotransplantation (TX).

248 to develop the vascularized brachial plexus allotransplantation (VBP-allo) model.

249 Vascularized composite allotransplantation (VCA) allows tissue replacement afte

250 r the last 2 decades, vascularized composite allotransplantation (VCA) has appeared for replacing tis

251 pticism, the field of vascularized composite allotransplantation (VCA) has demonstrated feasibility.

252 Vascularized composite tissue allotransplantation (VCA) has transformed patients' live

253 r immunomodulation in vascularized composite allotransplantation (VCA) have gained importance due to

254 Vascular composite allotransplantation (VCA) is a promising reconstructive

255 : Vascularized composite allotransplantation (VCA) is a relatively new field in r

256 A challenge in vascularized composite allotransplantation (VCA) is mitigating tissue damage wi

257 Vascularized composite allotransplantation (VCA) of the upper extremity is an e

258 olerance induction of vascularized composite allotransplantation (VCA) remains unclear.

259 med the potential for vascularized composite allotransplantation (VCA) to restore appearance, anatomy

260 imate model of facial vascularized composite allotransplantation (VCA) to study the association of Tr

261 y induce tolerance in vascularized composite allotransplantation (VCA) with chimerism through bone ma

262 n graft skin in human vascularized composite allotransplantation (VCA).

263 n graft skin in human Vascularized Composite Allotransplantation (VCA).

264 nfluence rejection in vascularized composite allotransplantation (VCA).

265 ression is needed for vascularized composite allotransplantation (VCA).

266 ially in the field of vascularized composite allotransplantation (VCA).

267 clinical expansion of vascularized composite allotransplantation (VCA).

268 omposite tissue loss, vascularized composite allotransplantation (VCA; e.g., hand and face transplant

269 ng process for vascularized composite tissue allotransplantation (VCTA) closely follows the standard

270 The clinic era of composite tissue allotransplantation was inaugurated by hand allotranspla

271 Historically, successful allotransplantation was only achieved by utilizing power

272 Life-supporting allotransplantation was performed in bilaterally nephrec

273 The allotransplantation was performed simultaneously on 2 ad

274 Left lung allotransplantation was performed, and recipients were m

275 Allotransplantation was then tested.

276 Using a well-characterized model of corneal allotransplantation, we demonstrate in this study that T

277 th research on penile vascularized composite allotransplantation will require the articulation of gui

278 These patients might be candidates for allotransplantation with (SLE)-resistant major histocomp

279 Profound T-cell depletion before allotransplantation with gradual posttransplant T-cell r

280 In response to airway allotransplantation with grafts expressing the OVA trans

281 in preventing acute rejection in adult liver allotransplantation with less renal toxicity and less us

282 In conclusion, allotransplantation with RIC or NMAC induces long-term p

283 aluated in19 monkeys that underwent auto- or allotransplantation, with or without subtherapeutic immu

284 in the context of experimental and clinical allotransplantation, with special emphasis on how this c